Omeros Corporation OMER today announced data from toxicology studies evaluating OMS721, the lead human monoclonal antibody in Omeros' mannan-binding lectin-associated serine protease-2 (MASP-2) ...
SEATTLE--(BUSINESS WIRE)-- Omeros Corporation (OMER) today announced the closing of the asset sale and licensing transaction between Omeros and Novo Nordisk for the candidate drug zaltenibart ...
Omeros Corporation Announces Closing of Asset Purchase and License Agreement with Novo Nordisk for Omeros’ Clinical-Stage MASP-3 Inhibitor Zaltenibart (OMS906) Omeros Corporation (Nasdaq: OMER) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results